1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Novavax, Inc.
  6. News
  7. Summary
    NVAX   US6700024010

NOVAVAX, INC.

(NVAX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Cowen Starts Novavax at Outperform With $150 Price Target

01/21/2022 | 07:53am EDT


© MT Newswires 2022
All news about NOVAVAX, INC.
05/24Indian vaccine giant Serum plans African plant in global expansion
RE
05/23Novavax Files in the European Union for Expanded Conditional Marketing Authorization of..
AQ
05/20SECTOR UPDATE : Health Care Stocks Rebound In Final Hour of Friday Trade
MT
05/20SECTOR UPDATE : Health Care Stocks Beginning to Sputter Amid Broader Markets Slide
MT
05/20Novavax Shares Drop After BofA Securities Begins Coverage at Underperform
MT
05/20EMA Starts Evaluation of Booster Dose Usage of Novavax's COVID-19 Vaccine
MT
05/20EMA Starts Evaluating Use Of Booster Dose Of Nuvaxovid In Adults
RE
05/20BofA Securities Initiates Coverage on Novavax With Underperform Rating
MT
05/16Novavax Files for Emergency Use Authorization of COVID-19 Vaccine in Taiwan
AQ
05/11TRANSCRIPT : Novavax, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-..
CI
More news
Analyst Recommendations on NOVAVAX, INC.
More recommendations
Financials (USD)
Sales 2022 4 278 M - -
Net income 2022 1 941 M - -
Net cash 2022 2 508 M - -
P/E ratio 2022 1,96x
Yield 2022 -
Capitalization 3 636 M 3 636 M -
EV / Sales 2022 0,26x
EV / Sales 2023 0,09x
Nbr of Employees 1 541
Free-Float 99,0%
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | NVAX | US6700024010 | MarketScreener
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 46,54 $
Average target price 154,86 $
Spread / Average Target 233%
EPS Revisions
Managers and Directors
Stanley C. Erck President, Chief Executive Officer & Director
James Patrick Kelly Chief Financial Officer, Treasurer & Executive VP
James F. Young Chairman
Gregory M. Glenn President-Research & Development
Biegie Lee Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
NOVAVAX, INC.-67.47%3 636
MODERNA, INC.-48.00%52 528
LONZA GROUP AG-27.13%42 896
IQVIA HOLDINGS INC.-28.41%38 232
SEAGEN INC.-13.67%24 569
ICON PUBLIC LIMITED COMPANY-30.17%17 581